Loading...
2267
XJPX
Market cap5.08bUSD
Nov 20, Last price  
2,835.00JPY
1D
-0.75%
1Q
-4.69%
Jan 2017
4.61%
Name

Yakult Honsha Co Ltd

Chart & performance

D1W1MN
XJPX:2267 chart
P/E
18.09
P/S
1.64
EPS
156.74
Vol. 1Y
30.17%
Shs. 5Y
-14.48%
Rev. 5Y
4.88%
Div Yld LY
2.29%
Div Yld TTM
2.57%
Revenues
489.49b
-2.04%
273,099,000,000317,335,000,000293,490,000,000290,678,000,000305,944,000,000312,552,000,000319,193,000,000350,322,000,000367,980,000,000390,412,000,000378,307,000,000401,569,000,000407,017,000,000406,004,000,000385,706,000,000415,116,000,000483,071,000,000503,079,000,000499,683,000,000489,486,773,000
Net income
44.51b
-2.25%
14,805,000,00016,675,000,00011,324,000,00013,248,000,00013,168,000,00013,291,000,00016,379,000,00022,543,000,00025,056,000,00028,843,000,00030,154,000,00034,064,000,00034,935,000,00039,735,000,00039,267,000,00044,917,000,00050,641,000,00051,006,000,00045,533,000,00044,506,390,000
CFO
52.45b
-38.07%
25,724,000,00025,177,000,00037,559,000,00039,535,000,00040,987,000,00033,444,000,00042,887,000,00048,579,000,00055,407,000,00062,149,000,00059,998,000,00061,989,000,00062,125,000,00062,791,000,00055,820,000,00073,390,000,00086,513,000,00070,702,000,00084,687,000,00052,449,073,000
Dividend
Mar 30, 202736 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Yakult Honsha Co.,Ltd. is a diversified Japanese enterprise engaged in the manufacturing and sale of a broad array of products, including food and beverages, cosmetics, and pharmaceuticals. The company's operations are segmented geographically for its Food and Beverages division, covering Japan, the Americas, Asia and Oceania, and Europe, alongside dedicated Pharmaceutical and "Others" segments. Its extensive food and beverage offerings feature popular items such as fermented milk beverages, various juices, and noodle products, which are distributed through both a home delivery service and traditional retail channels. In the pharmaceutical sector, Yakult Honsha provides specific medications like the antineoplastic drug Elplat, along with a suite of generic anti-cancer treatments, including Gemcitabine Yakult, Capecitabine, and Gefitinib Yakult tablets. Furthermore, the company maintains a presence in the cosmetics industry and is notably the owner of the professional baseball team, the Tokyo Yakult Swallows. Founded in 1935, Yakult Honsha Co.,Ltd. is headquartered in Tokyo, Japan.

Key people

Hiroshi Narita
President, Executive President, Representative Director · since 2021
Yasuyuki Suzuki
Senior Managing Executive Officer, Chief Director of Production, Director · since 2025
Hiroyuki Kawabata
Managing Executive Officer, Chief Director of Business Support, Director · since 2024
Masato Nagaoka
Managing Executive Officer, Director of Research Institute for Central · since 2025
Hiroaki Nagaoka
Managing Executive Officer · since 2024
Hiroshi Natsume
Managing Executive Officer · since 2024
Masakazu Seino
Managing Executive Officer · since 2025
Shuichi Watanabe
Managing Executive Officer, Director · since 2025
Yoshinobu Asakura
Executive Officer, Manager of Western Japan · since 2023
Osamu Chonan
Executive Officer · since 2023
Masaki Kaiya
Executive Officer · since 2023
Mitsuhisa Kawai
Executive Officer · since 2024
Naoki Komachi
Executive Officer · since 2023
Tomoyuki Masuda
Executive Officer · since 2025
Ken Nakano
Executive Officer, Manager of East Japan Office · since 2024
Ken Nishikawa
Executive Officer · since 2023
Tadashi Ohgo
Executive Officer · since 2024
Kan Shida
Executive Officer · since 2023
Jyun Tsukakoshi
Executive Officer · since 2025
Shunichi Uekusa
Executive Officer · since 2023
IPO date
Jan 23, 1980
Employees
29,880
Domiciled in
JP
Incorporated in
JP
Headquarters & legal address
海岸一丁目10番30号
東京都 港区 105-8660
JP
Address
10-30, Kaigan, 1-chome
Minato-ku Tokyo 105-8660
JP
Other language
YAKULT HONSHA CO., LTD.

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT